StockData
Northwest Biotherapeutics Inc logo

Northwest Biotherapeutics Inc (NWBO) stock

NWBOOTCPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 13, 2026Score 1/30
$0.16−0.00 (-0.88%)

Close on Oct 19, 2026Market cap $254.79MP/E –Yield –

Northwest Biotherapeutics total assets

Total assets on the balance sheet at the end of each period.

Northwest Biotherapeutics's total assets was $75.94M at Jun 30, 2026. For fiscal 2025 it was $81.29M, up 204.1% from the year before. Over ten years it grew 1.4% a year on average. The highest annual figure on record is $81.29M in fiscal 2025.

Annual total assets

PeriodPeriod endValueChange
FY2025Dec 31, 2025$81.29M+204.1%
FY2024Dec 31, 2024$26.73M-4.1%
FY2023Dec 31, 2023$27.87M-11.0%
FY2022Dec 31, 2022$31.32M-22.0%
FY2021Dec 31, 2021$40.16M+22.1%
FY2020Dec 31, 2020$32.90M+209.1%
FY2019Dec 31, 2019$10.64M-56.9%
FY2018Dec 31, 2018$24.67M-49.6%
FY2017Dec 31, 2017$48.91M-7.6%
FY2016Dec 31, 2016$52.91M-25.3%
FY2015Dec 31, 2015$70.80M+25.4%
FY2014Dec 31, 2014$56.46M+200.6%
FY2013Dec 31, 2013$18.78M+148.1%
FY2012Dec 31, 2012$7.57M+3470.8%
FY2011Dec 31, 2011$212.00K-27.9%
FY2010Dec 31, 2010$294.00K–

Quarterly total assets

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$75.94M+157.0%
Q1 FY2026Mar 31, 2026$80.05M+191.0%
Q4 FY2025Dec 31, 2025$81.29M+204.1%
Q3 FY2025Sep 30, 2025$30.61M+4.4%
Q2 FY2025Jun 30, 2025$29.55M+4.7%
Q1 FY2025Mar 31, 2025$27.51M-3.7%
Q4 FY2024Dec 31, 2024$26.73M-4.1%
Q3 FY2024Sep 30, 2024$29.32M-6.9%
Q2 FY2024Jun 30, 2024$28.23M-0.7%
Q1 FY2024Mar 31, 2024$28.57M-13.1%
Q4 FY2023Dec 31, 2023$27.87M-11.0%
Q3 FY2023Sep 30, 2023$31.49M+1.3%
Q2 FY2023Jun 30, 2023$28.44M+3.3%
Q1 FY2023Mar 31, 2023$32.87M+7.2%
Q4 FY2022Dec 31, 2022$31.32M-22.0%
Q3 FY2022Sep 30, 2022$31.10M+10.2%
Q2 FY2022Jun 30, 2022$27.52M-4.3%
Q1 FY2022Mar 31, 2022$30.66M-6.8%
Q4 FY2021Dec 31, 2021$40.16M+47.6%
Q3 FY2021Sep 30, 2021$28.22M+89.3%
Q2 FY2021Jun 30, 2021$28.77M+213.3%
Q4 FY2020Dec 31, 2020$32.90M+209.1%
Q3 FY2020Sep 30, 2020$27.21M+168.2%
Q2 FY2020Jun 30, 2020$14.91M+1.4%
Q1 FY2020Mar 31, 2020$9.18M-62.5%
Q4 FY2019Dec 31, 2019$10.64M-56.9%
Q3 FY2019Sep 30, 2019$10.15M-78.1%
Q2 FY2019Jun 30, 2019$14.70M-69.7%
Q1 FY2019Mar 31, 2019$24.47M-50.8%
Q4 FY2018Dec 31, 2018$24.67M-49.6%
Q3 FY2018Sep 30, 2018$46.33M-6.9%
Q2 FY2018Jun 30, 2018$48.48M-8.4%
Q1 FY2018Mar 31, 2018$49.78M+1.7%
Q4 FY2017Dec 31, 2017$48.91M-5.2%
Q3 FY2017Sep 30, 2017$49.75M-20.1%
Q4 FY2016Dec 31, 2016$52.91M-25.3%
Q3 FY2016Sep 30, 2016$48.94M–
Q2 FY2016Jun 30, 2016$51.61M–
Q1 FY2016Mar 31, 2016$62.23M–
Q4 FY2015Dec 31, 2015$70.80M–

More Northwest Biotherapeutics figures

See a number that looks wrong?